Trial Profile
A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Genentech
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2018 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.